Boston Therapeutics, Inc.
BTHE · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.11 | -0.02 | 0.01 |
| FCF Yield | -70.57% | -116.68% | -86.23% | -248.68% |
| EV / EBITDA | -12.44 | -1.58 | -1.42 | 20.80 |
| Quality | ||||
| ROIC | 20.99% | 100.15% | 521.14% | 448.61% |
| Gross Margin | -243.20% | -65.40% | -111.62% | 100.00% |
| Cash Conversion Ratio | 0.86 | 0.32 | 0.25 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -33.48% | -17.76% | -31.54% | -33.30% |
| Free Cash Flow Growth | 34.42% | -35.31% | 30.94% | -2.42% |
| Safety | ||||
| Net Debt / EBITDA | -10.11 | -1.26 | -1.04 | 17.08 |
| Interest Coverage | -1.83 | -10.20 | -2.79 | -0.76 |
| Efficiency | ||||
| Inventory Turnover | 14.40 | 6.91 | 66.27 | 0.00 |
| Cash Conversion Cycle | -6,022.56 | -8,197.47 | -2,761.94 | 7.31 |